Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations...
Canntab Therapeutics reported revenue of 293,362 CAD for fiscal year 2022, and net income of -3.69 million CAD. In Q3 2023 (the quarter ended February 28, 2023) revenue was -22,156 CAD, down 145.7% from a year before.
Figures from company filings; latest fiscal year ended May 31, 2022.
No profile data available.